Illumina, Inc.

ILMN

$300.8

-5.05% (1 year change)

Avg closing price

Price range

Market Cap

$43.9 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

-

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$4.35

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

69.17x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

-

Earnings before interest expenses and taxes in the last quarter.

Employees

7,700

The number of full time employees.

Revenue & Earnings

Balance Sheet

Illumina, Inc.

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

News

Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit

Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit

SAN DIEGO--(BUSINESS WIRE)--. Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeqâ„¢ 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. T...

Business Wire Business Wire, 11 days ago
Plant Genomics Market 2020: Global Industry Analysis, Regional Outlook, Size, Share, Growth, Trends and Forecast 2027|Leading Competitors- eurofins scientific, Illumina Inc, NRGene

Plant Genomics Market 2020: Global Industry Analysis, Regional Outlook, Size, Share, Growth, Trends and Forecast 2027|Leading Competitors- eurofins scientific, Illumina Inc, NRGene

Market Insights Having market research report is very essential for the business growth as it helps with the better decision making, enhancing revenue generation, prioritizing market goals and resu...

OpenPR OpenPR, 12 days ago
Corporate Matching $200K Challenge Through December 2020 at ACMG Foundation for Genetic and Genomic Medicine

Corporate Matching $200K Challenge Through December 2020 at ACMG Foundation for Genetic and Genomic Medicine

BETHESDA, Md., Nov. 5, 2020 /PRNewswire/ -- The ACMG Foundation for Genetic and Genomic Medicine (ACMG Foundation) launched the Illumina/ACMG Foundation $200K Challenge for the fourth quarter of 20...

PR Newswire PR Newswire, 19 days ago